Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Ivermectin ‘not clinically useful’ against Covid, study finds

Drug has become a cause celebre in parts of the vaccine-skeptical American right

Andrew Naughtie
Friday 18 March 2022 07:18 EDT
Comments
Human-grade ivermectin prepared for distribution in the Philippines
Human-grade ivermectin prepared for distribution in the Philippines (EPA-EFE)

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

A study of hundreds of Covid-19 patients has found that the drug ivermectin, often touted by vaccine skeptics as an alternative treatment for the disease, does not in fact provide infection against hospitalisation among those infected.

As reported by the Wall Street Journal, the study of more than 1,300 at-risk patients who visited clinics in Brazil has shown that those who were given the drug experienced no better results from the treatment than those who were given a placebo.

One of the study’s lead authors, Professor Edward Mills of Canada’s McMaster University, summed up the researchers’ findings bluntly, saying simply that “there is no indication that ivermectin is clinically useful”. Peter Hoetz of Baylor College of Medicine, who reviewed the study, remarked that it “should really help put to rest ivermectin and not give any credibility to the use of it for Covid-19”.

The paper detailing the study’s methodology and findings has been approved for publication in a major peer-reviewed journal, and will be presented at National Institutes of Health-sponsored forum today.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in